Skip NavigationSkip to Content
Return Return to Search Results

EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance

  1. Author:
    Suva, M. L.
    Riggi, N.
    Janiszewska, M.
    Radovanovic, I.
    Provero, P.
    Stehle, J. C.
    Baumer, K.
    Le Bitoux, M. A.
    Marino, D.
    Cironi, L.
    Marquez, V. E.
    Clement, V.
    Stamenkovic, I.

  2. Author Address

    [Suva, Mario-Luca; Riggi, Nicolo; Janiszewska, Michalina; Stehle, Jean-Christophe; Baumer, Karine; Le Bitoux, Marie-Aude; Cironi, Luisa; Stamenkovic, Ivan] Univ Lausanne, Inst Pathol, Div Expt Pathol, CH-1011 Lausanne, Switzerland. [Radovanovic, Ivan; Clement, Virginie] Univ Geneva, Dept Neurosurg, Geneva, Switzerland. [Provero, Paolo] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy. [Marquez, Victor E.] NCI, Ctr Canc Res, Frederick, MD 21701 USA.;Stamenkovic, I, Univ Lausanne, Inst Pathol, Div Expt Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland.;Ivan.Stamenkovic@chuv.ch
    1. Year: 2009
    2. Date: Dec
  2. Journal: Cancer Research
    1. 69
    2. 24
    3. Pages: 9211-9218
  4. Type of Article: Article
  5. ISSN: 0008-5472
  1. Abstract:

    Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2) occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma multiforme (GBM). Based on its ability to modulate transcription of key genes implicated in cell cycle control, DNA repair, and cell differentiation, EZH2 is believed to play a crucial role in tissue-specific stem cell maintenance and tumor development. Here, we show that targeted pharmacologic disruption of EZH2 by the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep), or its specific downregulation by short hairpin RNA (shRNA), strongly impairs GBM cancer stem cell (CSC) self-renewal in vitro and tumor-initiating capacity in vivo. Using genome-wide expression analysis of DZNep-treated GBM CSCs, we found the expression of c-myc, recently reported to be essential for GBM CSCs, to be strongly repressed upon EZH2 depletion. Specific shRNA-mediated downregulation of EZH2 in combination with chromatin immunoprecipitation experiments revealed that c-myc is a direct target of EZH2 in GBM CSCs. Taken together, our observations provide evidence that direct transcriptional regutation of c-myc by EZH2 may constitute a novel mechanism underlying GBM CSC maintenance and suggest that EZH2 may be a valuable new therapeutic target for GBM management. [Cancer Res 2009;69(24):9211-8]

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/0008-5472.can-09-1622
  3. View record in Web of Science®
  4. WOS: 000272920500009

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel